Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Soligenix, Inc. - Common Stock (NQ: SNGX )

2.300 -0.020 (-0.86%)
Streaming Delayed Price Updated: 3:59 PM EDT, Mar 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Soligenix, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
7 Stocks to Add to Your 10x Watchlist
It’s always a good time to look for stocks with exceptional growth potential. Here are seven 10x stocks for your watchlist. 
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Soligenix Positioned for Growth: Late-stage Pipeline and Key Q4 Milestones
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
UPDATE: Soligenix, Inc. to Showcase 2022 Milestones in Business Update Fireside Chat with PCG Advisory
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Exposures Product Safety
Recap: Soligenix Q2 Earnings
  Soligenix (NASDAQ:SNGX) reported its Q2 earnings results on Friday, August 12, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Soligenix Shares Gain On HyBrytes Data From Blood Cancer Study
Via Benzinga
Soligenix, Inc. to Showcase 2022 Milestones in Business Update Fireside Chat With PCG Advisory
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Exposures Product Safety
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Imara (NASDAQ:IMRA) stock moved upwards by 37.2% to $3.54 during Friday's pre-market session. The market value of their outstanding shares is at $93.0 million. 
Via Benzinga
Soligenix Enters Q4 With Multiple Catalysts in Play
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Exposures Product Safety
11 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Rubius Therapeutics (NASDAQ:RUBY) shares moved upwards by 30.46% to $0.59. The market value of their outstanding shares is at $53.5 million. 
Via Benzinga
FDA Awards $2.6 Million Grant for Expanded Study of Soligenix's HyBryte for CTCL
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Exposures Product Safety
Soligenix Earnings Perspective: Return On Capital Employed
According to Benzinga Pro data, during Q2, Soligenix (NASDAQ:SNGX) posted sales of $400 thousand. Earnings were up 45.12%, but Soligenix still reported an overall loss of $2.39 million. 
Via Benzinga
Could This Company's HyBryte™ Provide A Safer, More Convenient Alternative To Cutaneous T-Cell Lymphoma Treatment?
Patients always have hope if their cancers are detected early. Thanks to advanced research and therapies, the earlier the cancer is diagnosed and treated, the better the chance of it being cured. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers 
Via Benzinga
Daily Biotech Pulse: Teva's Opioids Settlement, Criminal Investigation Against Cassava, Durable Responses For IN8bio's Leukemia Therapy
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Soligenix's HyBryte Treatment Now Within Reach for Rare Cancer Patients
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Exposures Product Safety
Daily Biotech Pulse: KKR Invests In Medicine Start-Up, Revelation Bio Aces Allergic Rhinitis Study, Tonix Pharma Ends COVID-19 Antiviral Pact
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Soligenix Partners With SERB Pharmaceuticals To Supply Ricin Antigen For Ricin Toxin Poisoning Treatment
Via Benzinga
Recap of Wednesday's Biotech Catalysts - End of The Day Summary
  
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers 
Via Benzinga
Soligenix Gets FDA Nod For Mid-Stage Psoriasis Study
The U.S. Food and Drug Administration (FDA) has cleared Soligenix’s (NASDAQ: SNGX) Investigational New Drug (IND) application for Phase 2a clinical trial Evaluating SGX302 in the treatment of patients... 
Via Benzinga
The Daily Biotech Pulse: Kezar Life Surges On Positive Kidney Disease Trial Data, FDA Rejects Spero Therapeutics' Tebipenem, Graybug Reviews Strategic Alternatives
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Soligenix Moves Forward with Treatments for Cutaneous T-Cell Lymphoma and Psoriasis
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Soligenix, Inc. (NASDAQ: SNGX) Developing Treatments for Multiple Cancers, Vaccine Candidates (Ebola, Sudan, & Marburg)
Via Get News
Exposures COVID-19
Developing Treatments for Multiple Cancers; Vaccine Candidates (Ebola, Sudan, and Marburg) Plus a Novel Heat Stable COVID-19 & Ricin Toxin Vaccines: Soligenix, Inc. (NASDAQ: SNGX)
Via Viz Release
Exposures COVID-19
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.